China (Mainland)
Assessedsupplier
Newblue-CHEM 302962-49-8 Dasatinib CAS NO.302962-49-8
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,
- Product Details
Keywords
- 302962-49-8
- Dasatinib
- C22H28ClN7O3S
Quick Details
- ProName: Newblue-CHEM 302962-49-8 Dasatinib
- CasNo: 302962-49-8
- Molecular Formula: C22H28ClN7O3S
- Appearance: conform
- Application: 302962-49-8
- DeliveryTime: within 7 days after PO
- PackAge: normal package
- Port: any port in china
- ProductionCapacity: 1 Metric Ton/Day
- Purity: 99%min
- Storage: conform
- Transportation: by air
- LimitNum: 1 Kilogram
- Grade: Industrial Grade,Food Grade,Pharma Gra...
Superiority
Our company was built in 2009 with an ISO certificate.In the past 5 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:
1.Noble Metal Catalysts (Pt.Pd...)
2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)
3.OLED intermediates (Fluorene,Carbazole,Boric acid...)
4.Customs Synthesis
Our advantage:
1. Higest quality and good package
2.Fast delivery
3.Better payment term
4.Fast response to customer within 6 hours
5.Good business credit in Europe ,US ,Japan ,Korea
Anyway ,if you need any chemicals from China ,Henan Newblue can help you
Details
| Dasatinib Basic information |
| Product Name: | Dasatinib |
| Synonyms: | Dasatinib(BMS-354825);BMS-354825;N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide;5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-;Dasatinib;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide;2-{6-[4-(2-HYDROXY-ETHYL)-PIPERAZIN-1-YL]-2-METHYL-PYRIMIDIN-4-YLAMINO}-THIAZOLE-5-CARBOXYLIC ACID (2-CHLORO-6-METHYL-PHENYL)-AMIDE |
| CAS: | 302962-49-8 |
| MF: | C22H28ClN7O3S |
| MW: | 488.01 |
| EINECS: | |
| Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors;Pharmaceutical intermediate;Inhibitor;Sprycel;Anti-cancer&immunity;Inhibitors |
| Mol File: | 302962-49-8.mol |
|
|
|
| Dasatinib Chemical Properties |
| mp | 275-286°C |
| storage temp. | -20°C Freezer |
| CAS DataBase Reference | 302962-49-8(CAS DataBase Reference) |
| Safety Information |
| Dasatinib Usage And Synthesis |
| Leukemia drug |
Dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors. October 28, 2010 ,the FDA approved dasatinib (Sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed Philadelphia chromosome-positive called chronic myeloid leukemia (Ph + CP-CML) . The disease is a blood and bone marrow disease associated with genetic abnormality . An open-label randomized clinical trial conducted in patients with CP-CML evaluated the safety and efficacy of dasatinib . Common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, headache, musculoskeletal pain, and rash. October 11, 2011, the US Food and Drug Administration (FDA) said the leukemia drug dasatinib (Sprycel, Bristol-Myers Squibb Company) might increase pulmonary arterial hypertension (PAH) risk. Pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . PAH symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms from other similar symptoms. Since 2006 Dasatinib was approved in the US market ,there had been 12 associated pulmonary hypertension events ,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib. The above information is edited by the Chemicalbook of Tian Ye. |
| Chemical properties | White solid |
| Application | Suitable for treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate. |
| Chemical Properties | Pale-Yellow Solid |
| Usage | A new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML. Antineoplastic |
| Usage | Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.8 nM and 79 nM, respectively. |
| Dasatinib Preparation Products And Raw materials |